Despite of distinct clinical symptoms, the obese patients with different metabolic abnormalities shared some GM biomarker, such as Blautia, Dorea and Gemmiger. As an acetate producer36, Blautia can drive insulin release and promote metabolic syndromes, such as hypertriglyceridaemia, fatty liver disease and insulin resistance16. Here, INS is linked to metabolic syndrome.